StreetInsider.com News Articles

Organogenesis publishes PREPARE trial results for PuraPly AM wound treatment

Mon, 12 Oct 2026 16:10:40 -0400

Organogenesis Holdings Inc. (Nasdaq: ORGO) announced the publication of results from the PREPARE trial, a prospective, multicenter, randomized controlled trial evaluating PuraPly AM plus standard of care compared to standard of care alone in hard-to-heal diabetic foot ulcers.

The trial results, published in the Journal of Wound Care, showed statistically significant improvements in wound closure at 12 weeks among patients treated with PuraPly AM plus standard of care. The trial achieved its primary endpoint, according to a company statement.

Patrick Bilbo, Chief Operating Officer of Organogenesis, said the PREPARE study adds to existing data for PuraPly AM, including real-world evidence from registry

Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers

Mon, 12 Oct 2026 16:10:00 -0400

CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the publication of previously released results from PREPARE¹, a prospective, multicenter, randomized controlled trial (RCT) evaluating PuraPly^®AM (PCMP) plus standard of care (SoC) compared to SoC alone in hard-to-heal diabetic foot ulcers (DFUs). The trial achieved its primary endpoint, and the results published in the Journal of Wound Care demonstrate statistically significant improvements in wound closure at

Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers

Mon, 12 Oct 2026 16:10:00 -0400

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026

Mon, 12 Oct 2026 16:05:00 -0400

CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that third quarter of fiscal year 2026 financial results will be reported after the market closes on Thursday, November 5th.

Management will host a conference call at 5:00 p.m. Eastern Time on November 5th to discuss the results of the quarter, and to provide a corporate update with a

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026

Mon, 12 Oct 2026 16:05:00 -0400

Management will host a conference call at 5:00 p.m. Eastern Time on November 5th to discuss the results of the quarter, and to provide a corporate update with a

Form 8-K Organogenesis Holdings For: Aug 06

Tue, 11 Aug 2026 10:26:00 -0400

si-local-file:///var/storage/secattach/20260811/26903399.html

Form 8-K Organogenesis Holdings For: Aug 06

Tue, 11 Aug 2026 10:26:00 -0400

si-local-file:///var/storage/secattach/20260811/26903399.html

Form 424B5 Organogenesis Holdings

Tue, 11 Aug 2026 10:26:00 -0400

si-local-file:///var/storage/secattach/20260811/26903392.html

Form 424B5 Organogenesis Holdings

Tue, 11 Aug 2026 10:26:00 -0400

si-local-file:///var/storage/secattach/20260811/26903392.html

Form 8-K Organogenesis Holdings For: Aug 06

Thu, 06 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260806/26885065.html

Form 8-K Organogenesis Holdings For: Aug 06

Thu, 06 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260806/26885065.html

Organogenesis Holding (ORGO) Misses Q2 EPS by 42c

Thu, 06 Aug 2026 16:42:58 -0400

Organogenesis Holding (NASDAQ: ORGO) reported Q2 EPS of ($0.77), $0.42 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $42.8 million versus the consensus estimate of $54.25 million.

For earnings history and earnings-related data on Organogenesis Holding (ORGO) click here.

Form 424B5 Organogenesis Holdings

Thu, 06 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260806/26885009.html

Form 424B5 Organogenesis Holdings

Thu, 06 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260806/26885009.html

Form 10-Q Organogenesis Holdings For: Jun 30

Thu, 06 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260806/26884258.html

Form 10-Q Organogenesis Holdings For: Jun 30

Thu, 06 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260806/26884258.html

Form 8-K Organogenesis Holdings For: Aug 06

Thu, 06 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260806/26884092.html

Form 8-K Organogenesis Holdings For: Aug 06

Thu, 06 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260806/26884092.html

Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:05:00 -0400

CANTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 Financial Results Summary:

Net revenue of $42.8 million for the second quarter of 2026, a decrease of $58.0 million compared to net revenue of $100.8 million for the second quarter of 2025. Net revenue

Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:05:00 -0400

Second Quarter 2026 Financial Results Summary:

Net revenue of $42.8 million for the second quarter of 2026, a decrease of $58.0 million compared to net revenue of $100.8 million for the second quarter of 2025. Net revenue

Organogenesis publishes Affinity trial results for venous leg ulcers

Mon, 27 Jul 2026 16:05:14 -0400

Organogenesis Holdings Inc. (Nasdaq: ORGO) announced the publication of results from a randomized controlled trial evaluating its Affinity product in the treatment of complex venous leg ulcers (VLUs), according to a company statement.

The trial, published in the Journal of Wound Care, enrolled 206 patients randomized 1:1 to receive either Affinity plus standard of care (SoC) or SoC alone. Patients were followed for 24 weeks after a four-week run-in period.

The study examined two groups based on baseline wound duration: wounds present for more than six months and wounds present for more than 24 months. In both groups, patients receiving Affinity plus

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

Mon, 27 Jul 2026 16:05:00 -0400

CANTON, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced published results from a prospective, multicenter, randomized controlled trial (RCT) evaluating Affinity plus standard of care (SoC) compared to SoC alone in the management of complex venous leg ulcers (VLUs). The results were published in the Journal of Wound Care demonstrating statistically significant improvements in wound closure at weeks 12 and 16 for the Affinity + SoC group across two

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

Mon, 27 Jul 2026 16:05:00 -0400

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

Thu, 09 Jul 2026 07:30:00 -0400

CANTON, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that second quarter of fiscal year 2026 financial results will be reported after the market closes on Thursday, August 6th.

Management will host a conference call at 5:00 p.m. Eastern Time on August 6th to discuss the results of the quarter, and to provide a corporate update with a

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

Thu, 09 Jul 2026 07:30:00 -0400

Management will host a conference call at 5:00 p.m. Eastern Time on August 6th to discuss the results of the quarter, and to provide a corporate update with a